When neurologists first studied the brains of people with Alzheimer’s, more than 100 years ago, they spotted two abnormal clumps of proteins — beta-amyloid…
Diagnosed with Alzheimer’s and one of the relative few who has gotten a prescription for the new, disease-modifying anti-amyloid drug Leqembi? If you live…
There are different modalities of drugs, delivered in different formats, that work in different ways. One type of drug you may encounter often is…
Open your medicine cabinet, and you’ll see many examples of the most common type of medication on the market: Small molecule drugs such as…
TauRx’s experimental drug HMTM is designed to target tau protein, an Alzheimer’s biomarker protein that causes tangles to muck up the works in the…
It’s an exciting time for Alzheimer’s research, according to Madhav Thambisetty, senior investigator at the National Institute on Aging. “We’ve known for years that…
Prescription drugs and vaccines revolutionized health care, dramatically decreasing death from disease and improving quality of life across the globe. But how do researchers,…
The monoclonal antibody drugs targeting the brain’s amyloid plaques dominated the news cycle in 2023. Eisai and Biogen’s Leqembi was approved by the FDA…
The Food and Drug Administration has decided to postpone its decision on the approval of Eli Lilly’s candidate Alzheimer’s drug, donanemab. The delay has…
Alzheimer’s disease affects millions of people worldwide, and as the world’s population ages, that number is going up. But, the exact cause of Alzheimer’s…
Neurologists and Alzheimer’s research experts explain the side effect known as ARIA — or brain bleeds — associated with the use of anti-amyloid monoclonal antibody…
Want to boost your memory? Or control your dreams? It costs $50 to buy 90 pills of galantamine, a brain-boosting nootropic supplement that promises…
Believe it or not, Pfizer’s drug Viagra was originally designed to treat cardiovascular problems. Early on in clinical trials, men taking the drug became…
Biogen renounced ownership of their controversial anti-Alzheimer’s drug Aduhelm after years of dismal sales. The company is also halting an ongoing clinical trial set…
The process of finding new treatments for Alzheimer’s disease is one of trial and error — and every “failed” trial generates invaluable new data…